There are 2949 resources available
821P - Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study
Presenter: Andrew Dean
Session: E-Poster Display
Resources:
Abstract
823P - Extended follow-up of a real-world cohort of patients (pts) with BRCA mutation (BRCAm) relapsed epithelial ovarian cancer (EOC) receiving olaparib maintenance therapy: The GINECO RETROLA study
Presenter: Thibault de La Motte Rouge
Session: E-Poster Display
Resources:
Abstract
824P - Real-world-data (RWD) on platinum (Pt) outcomes after PARP inhibitors (PARPi) progression in high grade serous ovarian cancer (HGSOC) patients (p)
Presenter: Andrea Plaja Salarich
Session: E-Poster Display
Resources:
Abstract
825P - Olaparib maintenance therapy in routine clinical practice: Quality of life interim results of the non-interventional C-PATROL study in ovarian cancer patients in Germany
Presenter: Frederik Marmé
Session: E-Poster Display
Resources:
Abstract
826P - Comparative efficacy of first-line maintenance PARP inhibitors (PARPI) in advanced ovarian cancer (OC): A network meta-analysis
Presenter: Dalia Hammoud
Session: E-Poster Display
Resources:
Abstract
827P - First real-life data on olaparib in 1st line (1stL) maintenance BRCA1/2 mutated epithelial ovarian cancer (EOC) in France: Descriptive analysis of 201 patients (pts) enrolled in the cohort temporary authorization for use (ATUc)
Presenter: Charlotte Bellier
Session: E-Poster Display
Resources:
Abstract
828P - Expected versus observed response to platinum-based chemotherapy after poly (ADP-ribose) polymerase inhibitor treatment for relapsed ovarian cancer
Presenter: Thais Baert
Session: E-Poster Display
Resources:
Abstract
829P - Regorafenib (R) or tamoxifen (T) for platinum-sensitive recurrent ovarian cancer (PSROC) with rising CA125 and no evidence of clinical or radiological disease progression: A GINECO randomized phase II trial
Presenter: Olivier Tredan
Session: E-Poster Display
Resources:
Abstract
830P - Subanalysis of a randomized phase III study comparing trabectedin and PLD vs PLD alone in patients with recurrent ovarian cancer (ROC)
Presenter: Bradley Monk
Session: E-Poster Display
Resources:
Abstract
831P - Efficacy of platinum-based chemotherapy in platinum-resistant ovarian cancer: A systematic review with pooled analysis of outcomes
Presenter: Alexey Rumyantsev
Session: E-Poster Display
Resources:
Abstract